Insilico Medicine and SK Biopharmaceuticals announce an AI-powered drug discovery collaboration valued at up to $2.5 billion, focused on neuroimmune therapies. The companies describe Insilico as a clinical-stage generative AI-driven drug discovery company. Under the agreement, the parties pursue discovery efforts targeting disorders involving interactions between the nervous and immune systems, referred to as “neuroimmune” disorders.
Fortune reports on remarks by Insilico co-CEO Alex Zhavoronkov, who compares the company’s ambition in AI drug development to the role SpaceX played in aerospace innovation. PR Newswire provides additional deal framing, describing the collaboration as a significant partnership between the Massachusetts-based Insilico and South Korea’s SK Biopharmaceuticals.
Across the coverage, the central points are the size of the deal—up to $2.5 billion—and the therapeutic focus on neuroimmune conditions. The reports characterize the effort as leveraging generative AI to identify and develop potential drug candidates, while specific program targets and timelines are not detailed in the provided excerpts.
